Pharmacokinetics and pharmacodynamics integration of danofloxacin against Eschrichia coli in piglet ileum ultrafiltration probe model

被引:0
|
作者
Yuqi Yang
Ping Cheng
Tianshi Xiao
Jargalsaikhan Ulziikhutag
Hongxiao Yu
Jiarui Li
Ruimeng Liu
Ishfaq Muhammad
Xiuying Zhang
机构
[1] University Town,Pharmacology Teaching and Research Department, School of Basic Medicine, Guizhou University of Traditional Chinese Medicine
[2] Northeast Agricultural University,Heilongjiang Key Laboratory for Animal Disease Control and Pharmaceutical Development, Faculty of Basic Veterinary Science, College of Veterinary Medicine
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Improper use of antibiotics results in poor treatment and severe bacterial resistance. In this study, ultrafiltration probes were successfully placed in the ileum of piglets with the aid of anesthetic. After the fluoroquinolone antimicrobial drug danofloxacin (DAN) was intramuscularly administered, blood and ileum ultrafiltrate were collected at different time points and then determined by High Performance Liquid Chromatography (HPLC). Pharmacokinetics (PK) parameters for plasma and ileum ultrafiltrate were calculated by WinNonlin software. The DAN concentration in ileum ultrafiltrate was much higher than that in plasma during the period 1.2–48 h. The DAN concentration in plasma reached its maximum at 1.10 ± 0.03 h, but reached at 6.00 ± 0.00 h in the ileum ultrafiltrate. The mean Cmax of the ileum is 13.59 times that of plasma. The elimination half-life (T1/2β) in the ileum ultrafiltrate (6.84 ± 1.49 h) was shorter than those in plasma (7.58 ± 3.20 h). The MIC, MBC and MPC of DAN in MH broth against Escherichia coli (O158) were 0.5 µg/mL, 0.5 µg/mL and 4 µg/mL, respectively. Both in vitro and ex vivo kill curves indicated that the killing mechanism of DAN against E. coli is concentration-dependent. The AUC/MPC ratio is 21.33 ± 2.14. Mean PK/PD index (AUC24h/MIC) for ileum ultrafiltrate that achieved bacteriostatic, bactericidal, and eradication were 99.85, 155.57, and 218.02 h, respectively. Three different dosages (1.49 mg/kg, 2.42 mg/kg, and 3.24 mg/kg) were calculated respectively based on AUC24h/MIC ratio above, which might provide a novel approach to the rational design of dosage schedules.
引用
收藏
相关论文
共 50 条
  • [41] In vivo Pharmacokinetics/Pharmacodynamics Profiles for Appropriate Doses of Cefditoren pivoxil against S. pneumoniae in Murine Lung-Infection Model
    Igarashi, Yuki
    Kojima, Nana
    Takemura, Wataru
    Liu, Xiaoxi
    Morita, Takumi
    Mizukami, Yuki
    Enoki, Yuki
    Taguchi, Kazuaki
    Yokoyama, Yuta
    Nakamura, Tomonori
    Matsumoto, Kazuaki
    PHARMACEUTICAL RESEARCH, 2023, 40 (07) : 1789 - 1797
  • [42] Cefmetazole as an Alternative to Carbapenems Against Extended-Spectrum Beta-Lactamase-Producing Escherichia coli Infections Based on In Vitro and In Vivo Pharmacokinetics/Pharmacodynamics Experiments
    Wataru Takemura
    Sho Tashiro
    Marina Hayashi
    Yuki Igarashi
    Xiaoxi Liu
    Yuki Mizukami
    Nana Kojima
    Takumi Morita
    Yuki Enoki
    Kazuaki Taguchi
    Yuta Yokoyama
    Tomonori Nakamura
    Kazuaki Matsumoto
    Pharmaceutical Research, 2021, 38 : 1839 - 1846
  • [43] Pharmacokinetics and Pharmacodynamics of Fosfomycin and Its Activity against Extended-Spectrum-β-Lactamase-, Plasmid-Mediated AmpC-, and Carbapenemase-Producing Escherichia coli in a Murine Urinary Tract Infection Model
    Zykov, Ilya Nikolaevich
    Samuelsen, Orjan
    Jakobsen, Lotte
    Smabrekke, Lars
    Andersson, Dan I.
    Sundsfjord, Arnfinn
    Frimodt-Moller, Niels
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2018, 62 (06)
  • [44] Gnotobiotic Piglet Infection Model for Evaluating the Safe Use of Antibiotics against Escherichia coli O157:H7 Infection
    Zhang, Quanshun
    Donohue-Rolfe, Arthur
    Krautz-Peterson, Greice
    Sevo, Milica
    Parry, Nicola
    Abeijon, Claudia
    Tzipori, Saul
    JOURNAL OF INFECTIOUS DISEASES, 2009, 199 (04): : 486 - 493
  • [45] Efficacy of Cefquinome against Escherichia coli Environmental Mastitis Assessed by Pharmacokinetic and Pharmacodynamic Integration in Lactating Mouse Model
    Yu, Yang
    Fang, Jin-Tao
    Sun, Jian
    Zheng, Mei
    Zhang, Qing
    He, Jie-Shun
    Liao, Xiao-Ping
    Liu, Ya-Hong
    FRONTIERS IN MICROBIOLOGY, 2017, 8
  • [46] Integration of Pharmacokinetics, Pharmacodynamics, Safety, and Efficacy into Model-Informed Dose Selection in Oncology First-in-Human Study: A Case of Roblitinib (FGF401)
    Wilbaux, Melanie
    Yang, Shu
    Jullion, Astrid
    Demanse, David
    Porta, Diana Graus
    Myers, Andrea
    Meille, Christophe
    Gu, Yi
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 112 (06) : 1329 - 1339
  • [47] Pharmacokinetics-pharmacodynamics of cefepime and piperacillin-tazobactam against Escherichia coli and Klebsiella pneumoniae strains producing extended-spectrum β-lactamases:: Report from the ARREST program
    Ambrose, PG
    Bhavnani, SM
    Jones, RN
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (05) : 1643 - 1646
  • [48] Establishment of a pharmacokinetics and pharmacodynamics model of Schisandra lignans against hippocampal neurotransmitters in AD rats based on microdi-alysis liquid chromatography-mass spectrometry
    Zhang, Jinpeng
    Cui, Xinyuan
    Zhao, Shuo
    Chang, Zenghui
    Zhang, Junshuo
    Chen, Yufeng
    Liu, Jiale
    Sun, Guohao
    Wang, Yiyuan
    Liu, Yuanyuan
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [49] Pharmacodynamics of Piperacillin-Tazobactam/Amikacin Combination versus Meropenem against Extended-Spectrum β-Lactamase-Producing Escherichia coli in a Hollow Fiber Infection Model
    Islam, Kamrul
    Sime, Fekade B.
    Wallis, Steven C.
    Bauer, Michelle J.
    Naicker, Saiyuri
    Won, Hayoung
    Zowawi, Hosam M.
    Abu Choudhury, Md
    Shirin, Tahmina
    Habib, Zakir H.
    Harris, Patrick N. A.
    Flora, Meerjady S.
    Roberts, Jason A.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2022, 66 (09)
  • [50] Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli:: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model
    Odenholt, Inga
    Cars, Otto
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2006, 58 (05) : 960 - 965